Home » COVALENT GROUP, INC. ENTERS INTO COMBINATION AGREEMENT
COVALENT GROUP, INC. ENTERS INTO COMBINATION AGREEMENT
Covalent Group, Inc., a leader in the design and management of complex clinical
trials and patient disease registries for the pharmaceutical, biotechnology and
medical device industries, today announced that it has entered into a definitive
combination agreement with Remedium Oy ("Remedium"), a privately-held,
full-service clinical research organization ("CRO") based in Finland
with offices in 8 countries throughout Scandinavia, Central Europe, and Eastern
Europe.
Genetic
Engineering News
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May